High-throughput discovery of #epitope-specific #antibodies? There's a #LIBRAseq for that. Great collaborative effort led by @LaurenW_Science.
High-Throughput B Cell Epitope Determination by Next-Generation Sequencing https://t.co/mOF9nIepNV
#LIBRAseq with ligand blocking enables targeted discovery of functional (not just binding) #antibodies.
Double #ACE2-blockers for both #SARSCoV2 and #SARSCoV were also identified.
Easily generalizable for #mAb discovery aiming to block other types of antigen-ligand interactions
We have a postdoctoral opening in antibody discovery, with a special emphasis on the development and application of innovative #bioinformatics technologies.
Come do cutting-edge research in #antibody and #vaccine science in #Nashville, one of the hottest destinations in the US!
Out now in @CellReports: Potent neutralization of #SARSCoV2 variants of concern (including #Delta) by an #antibody with an uncommon genetic signature and structural mode of spike recognition https://t.co/S32vvFZmix
Out now in @CellReports: Potent neutralization of #SARSCoV2 variants of concern (including #Delta) by an #antibody with an uncommon genetic signature and structural mode of spike recognition https://t.co/S32vvFZmix
More #COVID19 News: Positive results from a Phase 3 trial in recently infected asymptomatic patients demonstrate the ability of our investigational antibody cocktail to reduce progression to symptomatic #COVID19. Learn more: https://t.co/rziZOWmcVi
Announcing our Phase 3 trial in advanced #CervicalCancer was stopped early after achieving its primary efficacy endpoint. Today’s milestone is a “first” for the cervical cancer community. Learn why: https://t.co/ePL40tmYfR CC: @Sanofi
Today, the FDA accepted for review our sBLA for a treatment for children aged 6 to 11 years with moderate-to-severe #asthma. Learn more: https://t.co/9udThffNN0 @sanofi
Today the FDA approved a first-of-its-kind treatment for people with #HoFH, an ultra #rare inherited form of high cholesterol. Read the full announcement: https://t.co/C7ojzpAH8v
Announcing with @Sanofi, the FDA has granted full approval to our #immunotherapy for patients with locally advanced #BasalCell Carcinoma (#BCC) and accelerated approval for patients with metastatic #BCC. Learn more: https://t.co/Zu8cicfaad
The FDA has issued an Emergency Use Authorization for our investigational antibody cocktail to treat mild to moderate #COVID19 in certain high-risk patients 12 years and older. Learn more: https://t.co/yNfOFPyLI0
Announcing positive data from 524 additional non-hospitalized #COVID19 patients in ongoing P2/3 study of Regeneron’s investigational antibody cocktail: https://t.co/FOVKNlZRn0